Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00477711
Status:
COMPLETED
Last Update Posted:
2015-05-19
First Post:
2007-05-22
Brief Title:
A Study of CetuximabErbitux With Cisplatin and CapecitabineXelodaas 1st Line Treatment in the Advanced Gastric Cancer
Sponsor:
Peking University
Organization:
Peking University
Organization Data
Organization:
Peking University
Class:
OTHER
Study ID:
EMR 62202-769
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Peking University
Lead Sponsor Class:
OTHER
Responsible Party:
Shen Lin
Responsible Party Title:
pro
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Peking University
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Merck Sharp Dohme LLC | INDUSTRY |